Skip to main content
SpringerLink
Log in

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a very common condition in children and often extends into the adult years. Drugs such as methylphenidate, amphetamines and atomoxetine are frequently prescribed as part of management. The use of these drugs has been increasing and significant clinical benefit is achieved but safety has been questioned. In this review, the cardiovascular safety of these drugs is examined with regard to effects on blood pressure (BP), heart rate (HR), ECG parameters and the risk of sudden death. Methylphenidate appears to cause minor increases in BP and HR. There are no strong data to suggest that methylphenidate increases the corrected QT interval (QTc). Amphetamines appear to cause minor increases in HR and BP over the long term. There is growing evidence to suggest that amphetamines do not cause statistically or clinically significant increases in QTc. Sudden death remains an extremely rare event and there is no clear evidence to attribute this to methylphenidate. Some data even suggest that the risk of sudden death in treated children may be less common than in the background population. Limited data suggest that atomoxetine may increase BP and HR in the short term; in the long term it appears to increase BP. The effects of atomoxetine on QTc remain uncertain. Use of this drug does not appear to be associated with sudden death. Because the current evidence is based on research that has not been specifically designed to investigate the cardiovascular effects of these drugs it is difficult to draw firm conclusions, and further work is required specifically to address these questions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000

    Google Scholar 

  2. Ford T, Goodman R, Meltzer H. The British child and adolescent mental health survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 2003 Oct; 42(10): 1203–11

    Article  PubMed  Google Scholar 

  3. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1992

    Google Scholar 

  4. National Institute for Health and Clinical Excellence. CG72 attention deficit hyperactivity disorder (ADHD): NICE guideline [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelineV2.pdf [Accessed 2009 Feb 16]

  5. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006 Apr 6; 354(14): 1445–8

    Article  PubMed  CAS  Google Scholar 

  6. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: What is a physician to do [see comment]? Pediatrics 2006 Sep; 118(3): 1215–9

    Article  PubMed  Google Scholar 

  7. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American heart association council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation 2008 May 6; 117(18): 2407–23

    Article  PubMed  Google Scholar 

  8. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group, Section on Cardiology and Cardiac, Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008 Aug; 122(2): 451–3

    Article  PubMed  Google Scholar 

  9. Kelly KL, Rapport MD, DuPaul GJ. Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children’s cardiovascular functioning. Int Clin Psychopharmacol 1988 Apr; 3(2): 167–81

    Article  PubMed  CAS  Google Scholar 

  10. Martin CA, Guenthner G, Bingcang C, et al. Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 Feb; 17(1): 63–73

    Article  PubMed  Google Scholar 

  11. Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005 Aug; 15(4): 637–54

    Article  PubMed  Google Scholar 

  12. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001 May; 40(5): 525–9

    Article  PubMed  CAS  Google Scholar 

  13. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84

    Article  PubMed  Google Scholar 

  14. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006 Jan; 160(1): 82–90

    Article  PubMed  Google Scholar 

  15. McGough JJ, McBurnett K, Bukstein O, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006 Jun; 16(3): 351–6

    Article  PubMed  Google Scholar 

  16. Greenhill LL, Findling RL, Swanson JM, ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder [abstract]. Pediatrics 2002 Mar; 109(3): E39

    Article  PubMed  Google Scholar 

  17. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001 Oct; 108(4): 883–92

    Article  PubMed  CAS  Google Scholar 

  18. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46(11): 1445–53

    Article  PubMed  Google Scholar 

  19. Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily ritalin and once-daily equasym XL with placebo in children with attention deficit/ hyperactivity disorder. Eur Child Adolesc Psychiatry 2006 Dec; 15(8): 450–9

    Article  PubMed  Google Scholar 

  20. Gau SS, Shen HY, Soong WT, et al. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006 Aug; 16(4): 441–55

    Article  PubMed  Google Scholar 

  21. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder [abstract]. Pediatrics 2003 Nov; 112(5): e404

    Article  PubMed  Google Scholar 

  22. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999 Apr; 56(4): 330–6

    Article  PubMed  CAS  Google Scholar 

  23. Wilens TE, Biederman J, Lerner M, Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004 Feb; 24(1): 36–41

    Article  PubMed  CAS  Google Scholar 

  24. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005 Oct; 44(10): 1015–23

    Article  PubMed  Google Scholar 

  25. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, 841 cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002 Nov; 22(8): 1107–31

    Article  PubMed  Google Scholar 

  26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980

    Google Scholar 

  27. Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003 Oct; 64(10): 1163–9

    Article  PubMed  CAS  Google Scholar 

  28. Lucas PB, Gardner DL, Wolkowitz OM, et al. Methylphenidate-induced cardiac arrhythmias [letter]. N Engl J Med 1986 Dec 4; 315(23): 1485

    PubMed  CAS  Google Scholar 

  29. Medicines and healthcare products regulatory agency. Drug analysis print: methylphenidate [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/CON024109?indexChar=M [Accessed 2008 Oct 28]

  30. Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 1992; 2(4): 279–90

    Article  PubMed  CAS  Google Scholar 

  31. Prasad S, Furr AJ, Zhang S, et al. Baseline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health 2007; 1(1): 11

    Article  PubMed  Google Scholar 

  32. Ilgenli TF, Congologlu A, Ozturk C, et al. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Adv Ther 2007 Jan–Feb; 24(1): 182–8

    Article  PubMed  CAS  Google Scholar 

  33. Rijnbeek PR, Witsenburg M, Schrama E, et al. New normal limits for the paediatric electrocardiogram. Eur Heart J 2001 Apr; 22(8): 702–11

    Article  PubMed  CAS  Google Scholar 

  34. Rappley MD, Moore JW, Dokken D. ADHD drugs and cardiovascular risk [author reply]. N Engl J Med 2006 May 25; 354(21): 2296–8

    Article  PubMed  CAS  Google Scholar 

  35. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics 2007 Jan; 119(1): 154–5

    Article  PubMed  Google Scholar 

  36. Gould M, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. Epub 2009 Jun 15

  37. Food and Drug Administration. Communication about ongoing safety review of stimulant medications used in children with attention deficit hyperactivity disorder [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm [Accessed 2009 Jul 24]

  38. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the General Practice Research Database. Drug Saf 2009; 32(11): 1089–96

    Article  PubMed  Google Scholar 

  39. Besag FMC. Attention-deficity hyperactivity disorder (ADHD) treatment and sudden death. Druf Saf 2009; 32(11): 1097–100

    Article  Google Scholar 

  40. Samuels JA, Franco K, Wan F, et al. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006 Jan; 21(1): 92–5

    Article  PubMed  Google Scholar 

  41. Spencer TJ, Biederman J, Wilens TE. Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr 2005 Oct; 10 (10 Suppl. 15): 14–21

    PubMed  Google Scholar 

  42. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/ hyperactivity disorder. Pediatrics 2002 Aug; 110 (2 Pt 1): 258–66

    Article  PubMed  Google Scholar 

  43. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005 Sep; 147(3): 348–54

    Article  PubMed  CAS  Google Scholar 

  44. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr 2005 Oct; 10 (10 Suppl. 15): 22–30

    PubMed  Google Scholar 

  45. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29(3): 450–63

    Article  PubMed  CAS  Google Scholar 

  46. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007 Mar 1; 61(5): 706–12

    Article  PubMed  CAS  Google Scholar 

  47. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008 Jul; 13(7): 614–20

    PubMed  Google Scholar 

  48. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Feb; 28(2): 266–79

    Article  PubMed  CAS  Google Scholar 

  49. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Aug; 45(8): 919–27

    Article  PubMed  Google Scholar 

  50. Medicines and healthcare products regulatory agency. Drug analysis print: dexamphetamine [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/CON024109?indexChar=D [Accessed 2008 Oct 6]

  51. Kelly RP, Yeo KP, Teng CH, et al. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. J Clin Pharmacol 2005 Jul; 45(7): 851–5

    Article  PubMed  CAS  Google Scholar 

  52. Stojanovski SD, Robinson RF, Baker SD, et al. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol (Phila) 2006; 44(3): 243–7

    Article  Google Scholar 

  53. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(3): 251–65

    Article  PubMed  CAS  Google Scholar 

  54. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26(10): 729–40 842

    Article  PubMed  CAS  Google Scholar 

  55. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7

    Article  PubMed  CAS  Google Scholar 

  56. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study [abstract]. Pediatrics 2001 Nov; 108(5): E83

    Article  PubMed  CAS  Google Scholar 

  57. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46(2): 242–51

    Article  PubMed  Google Scholar 

  58. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec 27; 65(12): 1941–9

    Article  PubMed  CAS  Google Scholar 

  59. Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 176–85

    Article  PubMed  Google Scholar 

  60. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006 Jul; 149(1): 112–9

    Article  PubMed  CAS  Google Scholar 

  61. Dworkin N. Increased blood pressure and atomoxetine [abstract]. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44(6): 510

    Article  PubMed  Google Scholar 

  62. National Heart Lung and Blood Institute. Report of the second task force on blood pressure control in children — 1987: task force on blood pressure control in children. National Heart, Lung and Blood Institute, Bethesda, Mayland. Pediatrics 1987; 79: 1–25

    Google Scholar 

  63. Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007 Jul; 50(1): 47–53

    Article  PubMed  CAS  Google Scholar 

  64. Medicines and Healthcare Products Regulatory Agency. Straterra (atomoxetine): preliminary assessment report December 2005 [online]. Available from URL: http://www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/con2024013.pdf [Accessed 2009 Jan 16]

  65. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [abstract]. Am J Psychiatry 2004 Apr; 161(4): 757

    Article  PubMed  Google Scholar 

  66. Rajesh AS, Bates G, Wright JG. Atomoxetine-induced electrocardiogram changes. Arch Dis Child 2006 Dec; 91(12): 1023–4

    Article  PubMed  CAS  Google Scholar 

  67. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22(3): 213–37

    Article  PubMed  CAS  Google Scholar 

  68. Medicines and Healthcare Products Regulatory Agency. Drug analysis print: atomoxetine [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/CON024109?indexChar=A [Accessed 2008 Oct 23]

  69. American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008 Aug; 29(4): 335

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Mary’s Hospital, London, UK

    Gary Stiefel

  2. SEPT: South Essex Partnership NHS Trust, Twinwoods Health Resource Centre, Milton Road, Bedford, MK41 6AT, UK

    Frank M.C. Besag

Authors
  1. Gary Stiefel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank M.C. Besag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank M.C. Besag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stiefel, G., Besag, F.M. Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder. Drug-Safety 33, 821–842 (2010). https://doi.org/10.2165/11536380-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11536380-000000000-00000

Keywords

Search

Navigation